<?xml version='1.0' encoding='utf-8'?>
<document id="28067454"><sentence text="Concomitant use of calcium channel blockers with dual antiplatelet therapy and re-hospitalization for acute coronary syndrome."><entity charOffset="19-26" id="DDI-PubMed.28067454.s1.e0" text="calcium" /></sentence><sentence text="Existing studies suggested that concomitant use of calcium channel blockers (CCBs) may interfere with the antiplatelet effect of clopidogrel"><entity charOffset="51-58" id="DDI-PubMed.28067454.s2.e0" text="calcium" /><entity charOffset="129-140" id="DDI-PubMed.28067454.s2.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.28067454.s2.e0" e2="DDI-PubMed.28067454.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28067454.s2.e0" e2="DDI-PubMed.28067454.s2.e1" /></sentence><sentence text=" The objective of this study was to examine the effect of concomitant use of CCBs and clopidogrel on risks of acute coronary syndrome (ACS) re-hospitalization in patients receiving percutaneous coronary intervention"><entity charOffset="86-97" id="DDI-PubMed.28067454.s3.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="Using the Taiwan National Health Insurance Research Database, we identified 51 925 patients who were admitted for newly diagnosed ACS, received percutaneous coronary intervention, and used clopidogrel within 1 year after discharge"><entity charOffset="189-200" id="DDI-PubMed.28067454.s5.e0" text="clopidogrel" /></sentence><sentence text=" We further stratified them into three groups based on their uses of guideline-recommended secondary prevention medications for ACS (fully, partially, and non-compliant groups) to assess the potential modification effect of guideline compliance" /><sentence text=" For each group, we conducted a 1:1 propensity score matching to minimize selection bias" /><sentence text=" Cox proportional hazard models were used to investigate the effect of concomitant use of CCBs (overall, subclasses, and individual CCBs) and clopidogrel on risks of ACS re-hospitalization"><entity charOffset="142-153" id="DDI-PubMed.28067454.s8.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="Concomitant use of CCBs in patients discharged with clopidogrel was significantly associated with a lower risk of ACS re-hospitalization in the fully compliant group (HRfully compliant  = 0"><entity charOffset="52-63" id="DDI-PubMed.28067454.s10.e0" text="clopidogrel" /></sentence><sentence text="82 [95% confidence interval 0" /><sentence text="75-0" /><sentence text="89], p &lt; 0" /><sentence text="001) but was associated with increased risk of ACS re-hospitalization in the non-compliant group (HRnon-compliant  = 1" /><sentence text="22 [1" /><sentence text="03-1" /><sentence text="45], p = 0" /><sentence text="0252)" /><sentence text="" /><sentence text="Different guideline compliance of secondary prevention medications could modify the potential drug-drug interaction between clopidogrel and CCBs"><entity charOffset="124-135" id="DDI-PubMed.28067454.s20.e0" text="clopidogrel" /></sentence><sentence text=" Concomitant use of CCBs and clopidogrel was significantly associated with increased risk of ACS re-hospitalization in ACS patients not compliant to guideline-recommended secondary prevention drugs"><entity charOffset="29-40" id="DDI-PubMed.28067454.s21.e0" text="clopidogrel" /></sentence><sentence text=" Copyright © 2017 John Wiley &amp; Sons, Ltd" /><sentence text="" /></document>